Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Scholar Rock Holding Corp

Healthcare US SRRK

45.33USD
0.69(1.55%)

Last update at 2026-06-04T20:00:00Z

Day Range

44.6546.11
LowHigh

52 Week Range

5.6221.17
LowHigh

Fundamentals

  • Previous Close 44.64
  • Market Cap823.86M
  • Volume835570
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-186.49600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -89.85100M
  • Diluted EPS TTM-2.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -134.50200M -131.79900M -86.48300M -51.00000M -49.32600M
Minority interest - - - - -
Net income -131.64800M -131.79900M -84.99200M -49.69700M -49.32600M
Selling general administrative 43.12M 40.27M 28.22M 20.82M 14.38M
Selling and marketing expenses - - - - -
Gross profit 33.19M 18.82M 15.40M 20.49M -36.31000M
Reconciled depreciation 2.99M 2.63M 1.49M 1.30M 0.81M
Ebit -137.35600M -129.92100M -88.36900M -55.84500M -51.49900M
Ebitda -134.37000M -127.29400M -86.87800M -54.54200M -50.69200M
Depreciation and amortization 2.99M 2.63M 1.49M 1.30M 0.81M
Non operating income net other -0.13200M -1.87800M 0.40M 3.54M -0.05600M
Operating income -134.37000M -129.92100M -86.87800M -54.54200M -50.69200M
Other operating expenses 167.56M 148.74M 102.28M 75.03M 50.69M
Interest expense -2.85400M 1.88M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - 1.42M
Net interest income - - - - 1.42M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.85400M 1.88M -1.49100M -1.30300M 1.37M
Total revenue 33.19M 18.82M 15.40M 20.49M 0.00000M
Total operating expenses 167.56M 148.74M 102.28M 75.03M 50.69M
Cost of revenue - - - 54.22M 36.31M
Total other income expense net -0.13200M -1.87800M 0.40M 3.54M -0.05600M
Discontinued operations - - - - -
Net income from continuing ops -134.50200M -131.79900M -86.48300M -51.00000M -49.32600M
Net income applicable to common shares -134.50200M -131.79900M -86.48300M -51.00000M -49.32600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 311.04M 358.17M 304.44M 388.31M 196.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7.18M 12.66M 12.32M 3.37M 27.72M
Total liab 85.82M 97.93M 132.37M 127.53M 83.48M
Total stockholder equity 225.22M 260.24M 172.07M 260.77M 112.90M
Deferred long term liab - - - - -
Other current liab 20.53M 24.54M 17.69M 14.97M 9.63M
Common stock 0.08M 0.05M 0.04M 0.03M 0.03M
Capital stock 0.08M 0.05M 0.04M 0.03M 0.03M
Retained earnings -676.42100M -510.63200M -376.13000M -244.33100M -157.84800M
Other liab - - - 33.20M 46.50M
Good will - - - - -
Other assets - 4.22M 343.57M 3.52M 2.60M
Cash 101.86M 103.28M 212.84M 160.36M 36.31M
Cash and equivalents - - - - -
Total current liabilities 32.74M 36.39M 64.30M 42.56M 32.81M
Current deferred revenue - - 33.19M 18.82M 20.92M
Net debt -40.03700M -33.87900M -135.77700M -103.21900M -31.00500M
Short term debt 8.74M 7.85M 8.98M 5.37M 1.14M
Short long term debt 1.33M - 1.58M - -
Short long term debt total 61.82M 69.40M 77.06M 57.14M 5.30M
Other stockholder equity 901.47M 771.70M 548.20M 505.07M 270.68M
Property plant equipment - 7.38M 9.56M 8.12M 8.62M
Total current assets 288.19M 328.02M 265.32M 344.40M 185.17M
Long term investments - - - - -
Net tangible assets - 260.24M 172.07M 260.77M 112.90M
Short term investments 178.08M 212.09M 40.16M 180.67M 121.14M
Net receivables 1.08M - - 0.00000M 25.00M
Long term debt 48.68M 49.74M 48.42M 24.68M 0.00900M
Inventory - - - - -25.00000M
Accounts payable 3.46M 3.99M 4.43M 3.41M 1.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.09M -0.88400M -0.03500M -0.00200M 0.04M
Additional paid in capital - - - - -
Common stock total equity - 0.05M 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -510.63200M -376.13000M -244.33100M -157.84800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.42M 4.22M 4.12M 3.52M 2.60M
Deferred long term asset charges - - - - -
Non current assets total 22.84M 30.14M 39.13M 43.90M 11.21M
Capital lease obligations 11.80M 19.65M 27.06M 32.46M 5.30M
Long term debt total - 49.74M 48.42M 24.68M 0.00900M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -170.63400M 139.56M -59.41000M -59.12900M -58.73900M
Change to liabilities 6.63M 4.91M 7.19M 1.05M 68.98M
Total cashflows from investing activities -171.69800M 134.31M -63.49800M -62.23600M -60.23100M
Net borrowings -0.97500M 24.98M 24.62M -0.36500M -0.67300M
Total cash from financing activities 194.83M 44.95M 247.82M 48.88M 94.27M
Change to operating activities -0.94500M -10.64000M -0.45600M 0.67M 3.38M
Net income -134.50200M -131.79900M -86.48300M -51.00000M -49.32600M
Change in cash -109.56000M 52.48M 124.05M -76.46800M 58.61M
Begin period cash flow 215.33M 162.86M 38.81M 115.27M 56.67M
End period cash flow 105.77M 215.33M 162.86M 38.81M 115.27M
Total cash from operating activities -132.69400M -126.78900M -60.27100M -63.11500M 24.57M
Issuance of capital stock 195.31M 13.10M 215.92M 48.35M 94.94M
Depreciation 2.99M 2.63M 1.49M 1.30M 0.81M
Other cashflows from investing activities - - - 0.00800M -58.73900M
Dividends paid - - - - -
Change to inventory - - -0.45600M 0.67M -
Change to account receivables - 0.00000M 25.00M -25.00000M -25.00000M
Sale purchase of stock 195.81M 19.99M 223.22M 49.26M 94.94M
Other cashflows from financing activities 0.49M 31.86M 31.90M 0.90M 0.00600M
Change to netincome 27.73M 23.17M 11.20M 7.96M 5.27M
Capital expenditures 1.06M 5.25M 4.09M 3.12M 1.49M
Change receivables - - 25.00M -25.00000M -
Cash flows other operating -34.12000M -26.95000M -18.56800M 3.96M -0.81300M
Exchange rate changes - - - - -
Cash and cash equivalents changes -109.56000M 52.48M 124.05M -76.46800M 58.61M
Change in working capital -34.38900M -28.44000M 11.24M -21.16500M 67.90M
Stock based compensation 27.70M 23.15M 11.18M 7.97M 5.21M
Other non cash items 5.51M 6.73M 2.44M -0.40100M -0.28900M
Free cash flow -133.75800M -132.03700M -64.35900M -66.23000M 23.08M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SRRK
Scholar Rock Holding Corp		 0.69 1.55% 45.33 - - 13.14 4.65 8.22 -4.9224
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corp

301 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Edward H. Myles M.B.A., MBA CFO, COO & Treasurer 1972
Dr. Jay T. Backstrom M.D., M.P.H. Pres, CEO & Director 1955
Ms. Catherine Hu VP of Investor Relations & Corp. Communications NA
Ms. Junlin Ho J.D. Gen. Counsel & Corp. Sec. 1979
Ms. Caryn Parlavecchio Chief HR Officer 1972
Ms. Lisa Amaya Price Sr. VP of HR NA
Dr. George G. Nomikos M.D., Ph.D. Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area NA
Ms. Erin Moore Sr. VP of Fin. 1975
Mr. Ryan Iarrobino Sr. VP of Clinical Devel. & Operations NA
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. Chief Medical Officer 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.